SCTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Scribe Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Sep 2, 2026
$19.39−0.69 (-3.44%)
Close on Oct 19, 2026
- Market cap
- $48.01M
- P/E (TTM)
- –
- Dividend yield
- –
About Scribe Therapeutics
Biological Products, (No Diagnostic Substances), SIC 2836
Scribe Therapeutics, Inc. is listed on Nasdaq under the ticker SCTX, in the SEC industry Biological Products, (No Diagnostic Substances). It is incorporated in Delaware and its fiscal year ends on December 31. Reported financials on StockData start in fiscal 2024.
Company profile
Company
- Legal name
- Scribe Therapeutics, Inc.
- Headquarters
- Alameda, CA
- Address
- 1150 Marina Village Pkwy 94501
- Phone
- (510) 454-0213
- Website
- scribetx.com
- Industry
- Biological Products, (No Diagnostic Substances)
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
Stock & identifiers
- Ticker
- SCTX
- Exchange
- Nasdaq
- IPO date
- Jul 27, 2026
- Shares outstanding
- 19M, Aug 31, 2026
- Filer category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- SEC CIK
- 1853921
- CUSIP
- 811033109
- ISIN
- US8110331092
- EIN
- 82-2157847
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Benjamin L. Oakes | President, CEO, Director | 506,602 |
| David Parrot | Chief Financial Officer | 2,666 |
| Svetlana Lucas | Chief Business Officer | 33,695 |
| Carl L. Gordon | Director | 348,825 |
| Advisors Llc Orbimed | Director | 348,825 |
| Capital GP VIII LLC OrbiMed | Director | – |
| Behzad Aghazadeh | Director | – |
| Capital Advisors LLC Avoro | Director | – |
| Ventures LLC Avoro | Director | 3,088,888 |
| Joshua Bleharski | Director | – |
| James Dean Watson | Director | – |
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Jul 27, 2026 | IPO | Initial public offering priced (424B4 prospectus) |
| Jul 21, 2026 | Listing | Registration of securities on an exchange (Form 8-A) |